Healthcare Equities

Jade Biosciences expects to launch Phase 1 trials for JADE301, a monoclonal antibody targeting autoimmune diseases, by March 31, 2027. The clinical milestone represents a key catalyst for the pre-revenue biotech as it advances its pipeline of potentially best-in-class therapeutics.

GSK is positioning Depemokimab, its ultra-long-acting anti-IL-5 biologic, for a late 2027 commercial launch in the rapidly expanding asthma therapeutics market. The pipeline milestone represents a significant revenue catalyst for the British pharma giant as it competes for dominance in a market projected to exceed $16 billion. Investors are watching the asset closely as a potential differentiator in GSK's respiratory franchise.